Dear Doctor
In preparation for Amgen’s
ALL WORKING GROUP
advisory board on May 25th,
We kindly ask you to check the pre-read file and then answer the following Survey
What is your perception on the OS data outcomes in MRD negative
patients?
What are your thoughts on the outcomes of the chemotherapy
regimen (modified E2993/UKALLXII) used in this trial compared to
your SOC?
Does a ~20% transplant rate correlate with your clinical
practice?
What will be the impact on transplantation if blinatumomab
becomes available in the 1st line?
What are the major differences between E1910 and your
SOC?
Thank you.
Your response was submitted successfully.